Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Yuva Biosciences Inc. currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners and 2 distinct art units. This structure suggests that the company's current applications are being reviewed independently within the USPTO's biotechnology divisions.
COLMAN THOMAS WELLES is the busiest examiner for the company, currently handling 1 pending office action. With 2 distinct examiners each managing a portion of the portfolio, the company is exposed to multiple examination styles. The 1 busiest examiner pending count confirms that the 2 pending office actions are distributed equally among the assigned staff.
For a practitioner, the involvement of 2 distinct art units within the Biotechnology & Pharmaceuticals sector may result in different procedural hurdles. Because each of the 2 pending office actions is under a different examiner, the prosecution strategy must be individualized. This lack of examiner concentration ensures that the progress of one application is not directly tied to the workload or tendencies of a single individual.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLES, COLMAN THOMAS | 1 | 29.2% | +64.2% |
| MELLER, MICHAEL V | 1 | 47.1% | +28.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17806014 | COMPOSITIONS AND METHODS FOR TREATING COVID-19 AND SYMPTOMS THEREOF | MELLER, MICHAEL V | 66d overdue |
| 18282719 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION | WELLES, COLMAN THOMAS | 41d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17806014 | COMPOSITIONS AND METHODS FOR TREATING COVID-19 AND SYMPTOMS THEREOF | MELLER, MICHAEL V | 66d overdue |
| 18282719 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION | WELLES, COLMAN THOMAS | 41d |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18282719 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION | WELLES, COLMAN THOMAS | 1612 | §101§102§103§112Other | Non-Final OA | 41d | Pending | Sep 18, 2023 |
| 17806014 | COMPOSITIONS AND METHODS FOR TREATING COVID-19 AND SYMPTOMS THEREOF | MELLER, MICHAEL V | 1655 | §102§103 | Non-Final OA | 66d overdue | Pending | Jun 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial